|
|
Volumn 4, Issue 1, 2003, Pages 69-71
|
|
Talaporfin: LS 11, LS11, ME 2906, mono-L-aspartyl chlorin e6, NP e6, NPE 6, taporfin sodium
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
NP E6;
PHOTOSENSITIZING AGENT;
TALAPORFIN;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC AGENT;
ASPARTIC ACID;
CHLORIN E6;
NEW DRUG;
PORPHYRIN;
RADIOSENSITIZING AGENT;
ARTICLE;
BILE DUCT CARCINOMA;
CLINICAL TRIAL;
DIARRHEA;
DRUG BLOOD LEVEL;
DRUG MARKETING;
DRUG STRUCTURE;
DRUG TISSUE LEVEL;
EDEMA;
ERYTHEMA;
EYE DISEASE;
HEADACHE;
HEARTBURN;
HUMAN;
LIGHT EMITTING DIODE;
NAUSEA;
NONHUMAN;
PHOTODYNAMIC THERAPY;
PHOTOSENSITIVITY;
PRIORITY JOURNAL;
PRURITUS;
SARCOMA;
SOLID TUMOR;
VOMITING;
ANIMAL;
CHEMISTRY;
NEOPLASM;
REVIEW;
STATISTICS;
ANIMALS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ASPARTIC ACID;
CHEMISTRY, PHARMACEUTICAL;
CLINICAL TRIALS;
DRUGS, INVESTIGATIONAL;
HUMANS;
NEOPLASMS;
PHOTOSENSITIZING AGENTS;
PORPHYRINS;
RADIATION-SENSITIZING AGENTS;
|
|
EID: 0041355262
PISSN: 11745886
EISSN: None
Source Type: Journal
DOI: 10.2165/00126839-200304010-00014 Document Type: Article |
|
Times cited : (5)
|
|
References (4)
|
